{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:12:20Z","timestamp":1788840740017,"version":"build-2803163510"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.coph.2026.102661","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T06:41:41Z","timestamp":1786084901000},"page":"102661","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Pharmacological basis of Edaravone\u2013Dexborneol neuroprotection: Integrated modulation of oxidative stress, neuroinflammation, and ferroptosis"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3093-8572","authenticated-orcid":false,"given":"Ahmed M.","family":"Abd-Eldayem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayar.","family":"Ahmed Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2026.102661_bib1","article-title":"Efficacy analysis of neuroprotective drugs in patients with acute ischemic stroke based on network meta-analysis","volume":"15","author":"Li","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.coph.2026.102661_bib2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.apsb.2024.10.004","article-title":"Oxidative stress and inflammation in the pathogenesis of neurological disorders: mechanisms and implications","volume":"15","author":"Dash","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.coph.2026.102661_bib3","article-title":"The neurotoxicity of acrylamide in ultra-processed foods: interventions of polysaccharides through the microbiota-gut-brain axis","author":"Cai","year":"2024","journal-title":"Food Funct"},{"key":"10.1016\/j.coph.2026.102661_bib4","doi-asserted-by":"crossref","DOI":"10.31083\/JIN26458","article-title":"Mechanisms associated with mitophagy and ferroptosis in cerebral Ischemia-reperfusion injury","volume":"24","author":"Ma","year":"2025","journal-title":"J Integr Neurosci"},{"key":"10.1016\/j.coph.2026.102661_bib5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.22141\/2224-0586.21.1.2025.1828","article-title":"Complications of reperfusion therapy of acute ischemic stroke (scientific review)","volume":"21","author":"Dubenko","year":"2025","journal-title":"Emerg Med"},{"key":"10.1016\/j.coph.2026.102661_bib6","first-page":"190","article-title":"Clinical study of Edaravone Dexborneol combined with Tirofiban in treatment of Acute Cerebral Infarction","volume":"40","author":"Mi","year":"2024","journal-title":"Pakistan J Med Sci"},{"key":"10.1016\/j.coph.2026.102661_bib7","article-title":"Safety and efficacy of neuroprotective agents as adjunctive therapies for reperfusion in the treatment of acute ischemic stroke: a systematic review and meta-analysis of randomized controlled trials","author":"Zhang","year":"2025","journal-title":"J Neurosurg Anesthesiol"},{"key":"10.1016\/j.coph.2026.102661_bib8","article-title":"Neuroprotective agents with reperfusion therapies in ischemic stroke: evidence from recent randomized trials","volume":"17","author":"Wesley","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.coph.2026.102661_bib9","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.3390\/ijms25052945","article-title":"Update on antioxidant therapy with edaravone: expanding applications in neurodegenerative diseases","volume":"25","author":"Yamashita","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coph.2026.102661_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109315","article-title":"Edaravone dexborneol provides neuroprotective benefits by suppressing NLRP3 inflammasome-induced microglial pyroptosis in experimental ischemic stroke","volume":"113","author":"Hu","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.coph.2026.102661_bib11","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1007\/s11064-023-03973-1","article-title":"Edaravone dexborneol alleviates neuroinflammation by reducing neuroglial cell proliferation and suppresses neuronal Apoptosis\/Autophagy in vascular dementia rats","volume":"48","author":"Zhang","year":"2023","journal-title":"Neurochem Res"},{"key":"10.1016\/j.coph.2026.102661_bib12","first-page":"90","article-title":"Efficacy and safety of Y-2 sublingual tablet for patients with acute ischaemic stroke: protocol of a phase III randomised double-blind placebo-controlled multicentre trial","volume":"9","author":"Fu","year":"2024","journal-title":"Stroke Vasc Neurol"},{"key":"10.1016\/j.coph.2026.102661_bib13","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1001\/jama.2024.0526","article-title":"Adjunctive steroids as stroke reperfusion strategy","volume":"331","author":"Siegler","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.coph.2026.102661_bib14","doi-asserted-by":"crossref","DOI":"10.1007\/s11033-024-09952-1","article-title":"Potential of Edaravone Dexborneol in the treatment of cerebral ischemia: focus on cell death-related signaling pathways","volume":"51","author":"Rahmati-Dehkordi","year":"2024","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.coph.2026.102661_bib15","article-title":"Edaravone combined with Shuxuening versus edaravone alone in the treatment of acute cerebral infarction: a systematic review and meta-analysis","volume":"102","author":"Li","year":"2023","journal-title":"M\u00e9d Sur"},{"key":"10.1016\/j.coph.2026.102661_bib16","article-title":"Edaravone dexborneol protected neurological function by targeting NRF2\/ARE and NF-\u03baB\/AIM2 pathways in cerebral ischemia\/reperfusion injury","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.coph.2026.102661_bib17","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.freeradbiomed.2024.03.019","article-title":"Edaravone dexborneol protects against cerebral ischemia\/reperfusion-induced blood-brain barrier damage by inhibiting ferroptosis via activation of nrf-2\/HO-1\/GPX4 signaling","volume":"217","author":"Xiao","year":"2024","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.coph.2026.102661_bib18","article-title":"Edaravone dexborneol attenuates oxidative stress in experimental subarachnoid hemorrhage via Keap1\/Nrf2 signaling pathway","volume":"15","author":"Zhu","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.coph.2026.102661_bib19","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.freeradbiomed.2024.10.309","article-title":"Edaravone Dexborneol protects against blood-brain barrier disruption following cerebral ischemia\/reperfusion by upregulating pericyte coverage via vitronectin-integrin and PDGFB\/PDGFR-\u03b2 signaling","volume":"225","author":"Sun","year":"2024","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.coph.2026.102661_bib20","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1136\/svn-2023-002938","article-title":"Rationale and design of Treatment of Acute Ischaemic Stroke with Edaravone Dexborneol II (TASTE-2): a multicentre randomised controlled trial","volume":"9","author":"Wang","year":"2024","journal-title":"Stroke Vasc Neurol"},{"key":"10.1016\/j.coph.2026.102661_sref21","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1001\/jamaneurol.2023.5716","article-title":"Sublingual edaravone dexborneol for the treatment of acute ischemic stroke: the TASTE-SL randomized clinical trial","volume":"81","author":"Fu","year":"2024","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.coph.2026.102661_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2024.110006","article-title":"Edaravone Dexborneol ameliorates the cognitive deficits of APP\/PS1 mice by inhibiting TLR4\/MAPK signaling pathway via upregulating TREM2","volume":"255","author":"Wang","year":"2024","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.coph.2026.102661_bib23","doi-asserted-by":"crossref","first-page":"6647","DOI":"10.1007\/s00210-024-03045-3","article-title":"Edaravone dexborneol promotes M2 microglia polarization against lipopolysaccharide-induced inflammation via suppressing TLR4\/MyD88\/NF-\u03baB pathway","volume":"397","author":"Huang","year":"2024","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.coph.2026.102661_bib24","first-page":"1560","article-title":"Molecular changes in the ischemic brain as non-invasive brain stimulation Targets\u2014TMS and tDCS mechanisms, therapeutic challenges, and combination therapies","volume":"12","author":"Battaglia","year":"2024","journal-title":"Biomed"},{"key":"10.1016\/j.coph.2026.102661_bib25","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-025-06157-3","article-title":"Edaravone dexborneol alleviates pericyte-mediated fibrosis depositing extracellular matrix through TGF-\u03b21\/IL-11 in cerebral small vessel disease","volume":"23","author":"Duan","year":"2025","journal-title":"J Transl Med"},{"key":"10.1016\/j.coph.2026.102661_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/rcm.10050","article-title":"HR-MS analysis of the covalent binding of edaravone to 5-Formylpyrimidine bases and a DNA oligonucleotide containing a 5-Formylcytidine residue","volume":"39","author":"Regnault","year":"2025","journal-title":"Rapid Commun Mass Spectrom"},{"key":"10.1016\/j.coph.2026.102661_bib27","doi-asserted-by":"crossref","first-page":"637","DOI":"10.31925\/farmacia.2025.3.10","article-title":"Impact OF edaravone dexborneol treatment on neurological function, cognitive function, and inflammatory-oxidative stress status in patients with acute progressive cerebral infarction","volume":"73","author":"Fan","year":"2025","journal-title":"Farmacia Journal. Farmacia"},{"key":"10.1016\/j.coph.2026.102661_bib28","doi-asserted-by":"crossref","DOI":"10.1007\/s11033-025-10343-3","article-title":"Edaravone reduces brain injury in hepatic encephalopathy by upregulation of Nrf2\/HO-1 and inhibition of NF-\u03baB, iNOS\/NO and inflammatory cytokines","volume":"52","author":"Amirshahrokhi","year":"2025","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.coph.2026.102661_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/adbi.202400501","article-title":"Edaravone alleviates BV-2 microglia-mediated neuroinflammation through the PI3K\/AKT\/NF-\u03baB pathway","volume":"9","author":"Yang","year":"2025","journal-title":"Adv Biol"},{"key":"10.1016\/j.coph.2026.102661_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2025.156521","article-title":"Gang: (+)-Borbeol enhances the protective effect of edaravone against cerebral ischemia\/reperfusion injury by targeting OAT3\/P-gp transporters for drug delivery into the brain","volume":"139","author":"Wang","year":"2025","journal-title":"Phytomedicine"},{"key":"10.1016\/j.coph.2026.102661_bib31","doi-asserted-by":"crossref","DOI":"10.1007\/s11940-025-00845-7","article-title":"Effectiveness and safety of edavarone and dexborneol in acute ischemic stroke: a systematic review","volume":"27","author":"Aderinto","year":"2025","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.coph.2026.102661_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainresbull.2024.111097","article-title":"Edaravone Dexborneol provides neuroprotective effect by inhibiting neurotoxic activation of astrocytes through inhibiting NF-\u03baB signaling in cortical ischemia","volume":"218","author":"Chen","year":"2024","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.coph.2026.102661_bib33","doi-asserted-by":"crossref","DOI":"10.1159\/000542011","article-title":"Combined selective endovascular brain hypothermia with edaravone dexborneol versus edaravone dexborneol alone for endovascular treatment in acute ischemic stroke (SHE): protocol for a multicenter, single-blind, randomized controlled study","author":"Jiang","year":"2024","journal-title":"Cerebrovasc Dis"},{"key":"10.1016\/j.coph.2026.102661_bib34","doi-asserted-by":"crossref","first-page":"72","DOI":"10.36740\/WLek202101114","article-title":"Acute ischemic stroke in women: efficacy of the free radical scavenger edaravone","volume":"74","author":"Vdovychenko","year":"2021","journal-title":"Wiad Lek"},{"key":"10.1016\/j.coph.2026.102661_bib35","first-page":"1092","article-title":"The effect of edaravone supplementation prior to cryopreservation on sperm parameters, DNA integrity, apoptosis, lipid peroxidation, and mitochondrial membrane potential in infertile men with asthenoteratozoospermia","volume":"324","author":"Ghasemi","year":"2025","journal-title":"Reprod Sci 2025"},{"key":"10.1016\/j.coph.2026.102661_sref36","article-title":"Edaravone: advances on cytoprotective effects, pharmacological properties, and mechanisms of action","volume":"78","author":"Dakroub","year":"2026","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.coph.2026.102661_bib37","doi-asserted-by":"crossref","first-page":"8965","DOI":"10.1007\/s12035-025-04815-7","article-title":"Exploring the nexus: how ferroptosis, microglia, and neuroinflammation converge in ischemic stroke pathogenesis","volume":"627","author":"Liu","year":"2025","journal-title":"Mol Neurobiol 2025"},{"key":"10.1016\/j.coph.2026.102661_sref38","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.125.044296","article-title":"Edaravone dexborneol in large ischemic stroke: Real-World experience from a multicenter Study in China","volume":"15","author":"Ma","year":"2026","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.coph.2026.102661_sref39","first-page":"392","article-title":"Edaravone dexborneol versus placebo on functional outcomes in patients with acute ischaemic stroke undergoing endovascular thrombectomy (TASTE-2): randomised controlled trial","author":"Wang","year":"2026","journal-title":"Br Med J"},{"key":"10.1016\/j.coph.2026.102661_sref40","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1161\/STROKEAHA.120.031197","article-title":"Edaravone dexborneol versus edaravone alone for the treatment of acute ischemic stroke: a phase III, randomized, Double-Blind, comparative trial","volume":"52","author":"Xu","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.coph.2026.102661_bib41","article-title":"Edaravone dexborneol compared to edaravone in the treatment of acute cerebral infarction: a meta-analysis","volume":"16","author":"Shi","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.coph.2026.102661_bib42","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1248\/bpb.b22-00186","article-title":"Edaravone ameliorates cerebral ischemia-reperfusion injury by downregulating ferroptosis via the Nrf2\/FPN pathway in rats","volume":"45","author":"Liu","year":"2022","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.coph.2026.102661_bib43","first-page":"202512","article-title":"Fundamental mechanism of ferroptosis: three unanswered questions","volume":"2","author":"Feinsod","year":"2026","journal-title":"Ferroptosis Oxidative Stress"},{"key":"10.1016\/j.coph.2026.102661_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11684-024-1080-8","article-title":"Ferroptosis contributes to immunosuppression","volume":"19","author":"He","year":"2025","journal-title":"Front Med"},{"key":"10.1016\/j.coph.2026.102661_bib45","doi-asserted-by":"crossref","DOI":"10.1007\/s11011-025-01559-0","article-title":"Edaravone dextranol alleviates ferroptosis, cuproptosis, and blood-brain barrier damage after acute cerebral infarction","volume":"40","author":"Jin","year":"2025","journal-title":"Metab Brain Dis"},{"key":"10.1016\/j.coph.2026.102661_bib46","first-page":"1","article-title":"Edaravone dexborneol provides neuroprotective benefits by suppressing ferroptosis in experimental intracerebral hemorrhage","volume":"15","author":"Li","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.coph.2026.102661_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e39684","article-title":"Improving understanding of ferroptosis: molecular mechanisms, connection with cellular senescence and implications for aging","volume":"10","author":"De Leon-Oliva","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.coph.2026.102661_bib48","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/ar.25296","article-title":"Edaravone dexborneol alleviates cerebral ischemia-reperfusion injury through NF-\u03baB\/NLRP3 signal pathway","volume":"307","author":"Shen","year":"2024","journal-title":"Anat Rec"},{"key":"10.1016\/j.coph.2026.102661_bib49","first-page":"31","article-title":"Effect of edaravone dexborneol combined with interventional thrombectomy on nerve function, cerebral hemodynamics, and serum levels of serum amyloid A, lipoprotein-associated phospholipase A2, and soluble CD40 ligand in elderly patients with ischemic str","volume":"76","author":"Zhou","year":"2025","journal-title":"J Physiol Pharmacol an Off J Polish Physiol Soc"},{"key":"10.1016\/j.coph.2026.102661_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2025.1681859","article-title":"Edaravone Dexborneol in acute ischemic stroke patients treated with combined intravenous thrombolysis and mechanical thrombectomy for large vessel occlusion","volume":"16","author":"Peng","year":"2025","journal-title":"Front Neurol"},{"key":"10.1016\/j.coph.2026.102661_bib51","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/3855698","article-title":"Edaravone dexborneol downregulates neutrophil extracellular trap expression and ameliorates blood-brain barrier permeability in acute Ischemic stroke","volume":"2022","author":"Huang","year":"2022","journal-title":"Mediat Inflamm"},{"key":"10.1016\/j.coph.2026.102661_bib52","doi-asserted-by":"crossref","first-page":"111","DOI":"10.5152\/pcp.2025.24987","article-title":"The effects of cinepazide maleate in conjunction with edaravone on cerebral blood flow and neurofunctional parameters in individuals with acute ischemic stroke","volume":"35","author":"Tian","year":"2025","journal-title":"Psychiatry Clin Psychopharmacol"},{"key":"10.1016\/j.coph.2026.102661_bib53","doi-asserted-by":"crossref","DOI":"10.1515\/tnsci-2022-0312","article-title":"Effects of edaravone dexborneol on neurological function and serum inflammatory factor levels in patients with acute anterior circulation large vessel occlusion stroke","volume":"14","author":"Hu","year":"2023","journal-title":"Transl Neurosci"},{"key":"10.1016\/j.coph.2026.102661_bib54","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1136\/svn-2018-000221","article-title":"Safety and efficacy of Edaravone Dexborneol versus edaravone for patients with acute ischaemic stroke: a phase II, multicentre, randomised, double-blind, multiple-dose, active-controlled clinical trial","volume":"4","author":"Xu","year":"2019","journal-title":"Stroke Vasc Neurol"},{"key":"10.1016\/j.coph.2026.102661_sref55","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s12883-024-03712-1","article-title":"Effects of edaravone dexborneol on functional outcome and inflammatory response in patients with acute ischemic stroke","volume":"24","author":"Chen","year":"2024","journal-title":"BMC Neurol"},{"key":"10.1016\/j.coph.2026.102661_bib56","doi-asserted-by":"crossref","DOI":"10.1080\/00207454.2026.2628832","article-title":"Evaluating the efficacy and safety of Edaravone-Dexborneol in acute ischemic stroke: an updated systematic review and meta-analysis of 7,846 Chinese patients","author":"Sabet","year":"2026","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.coph.2026.102661_bib57","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4103\/\/ANT.33-1_111_0067","article-title":"Antioxidant and apoptotic effect of edaravone on cisplatin-induced brain injury in rats","volume":"33","author":"Kara","year":"2024","journal-title":"Acta Neurol Taiwan"},{"key":"10.1016\/j.coph.2026.102661_bib58","article-title":"Edaravone inhibits inflammation in toll-like receptor 4-Stimulated PBMNCs from multiple sclerosis patients","volume":"8","author":"Antunes","year":"2025","journal-title":"J Mol Clin Med 2025"},{"key":"10.1016\/j.coph.2026.102661_bib59","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1007\/s44411-025-00195-5","article-title":"A low dose of edaravone decreases the epileptiform activity in the absence epilepsy model by reducing oxidative stress and neuroinflammation","volume":"126","author":"Tun\u00e7","year":"2025","journal-title":"Bratisl Med J"},{"key":"10.1016\/j.coph.2026.102661_bib60","doi-asserted-by":"crossref","DOI":"10.1186\/s12920-025-02098-4","article-title":"Analysis of ferroptosis-related genes in cerebral ischemic stroke via immune infiltration and single-cell RNA-sequencing","volume":"18","author":"Fan","year":"2025","journal-title":"BMC Med Genom"},{"key":"10.1016\/j.coph.2026.102661_bib61","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13195-025-01777-9","article-title":"Edaravone-Dexborneol slows down pathological progression and cognitive decline via inhibiting S100A9 in APPswe\/PS1dE9 mice","volume":"17","author":"Mao","year":"2025","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.coph.2026.102661_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114511","article-title":"Edaravone alleviates Pseudomonas aeruginosa associated-acute lung injury by inhibiting inflammation and promoting anti-microbial peptide production","volume":"154","author":"Song","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.coph.2026.102661_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2025.156558","article-title":"Edaravone dexborneol exerts anti-epileptic effects on rodent temporal lobe epilepsy by promoting NMDAR deactivation and inhibiting oxidative stress","volume":"140","author":"Qiu","year":"2025","journal-title":"Phytomedicine"},{"key":"10.1016\/j.coph.2026.102661_bib64","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13051047","article-title":"Edaravone Attenuates sleep deprivation-induced memory deficits by inhibiting oxidative stress and neuroinflammation in Murine models","volume":"13","author":"Ji","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.coph.2026.102661_bib65","doi-asserted-by":"crossref","DOI":"10.1007\/s12311-025-01804-3","article-title":"Differential protective effects of edaravone in cerebellar and hippocampal ischemic injury models","volume":"24","author":"Dickmei\u00df","year":"2025","journal-title":"Cerebellum"},{"key":"10.1016\/j.coph.2026.102661_bib66","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1007\/s12035-024-04541-6","article-title":"Acute administration of edaravone improves cognitive impairment in a mouse model of mPFC ischemia: crosstalk between necroptosis, neuroinflammation, and antioxidant defense","volume":"62","author":"Barati","year":"2025","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.coph.2026.102661_bib67","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1080\/00207454.2024.2328730","article-title":"Advantages of edaravone dextrosanol in elderly patients with acute cerebral infarction versus edaravone: a preliminary study","volume":"135","author":"Zhu","year":"2025","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.coph.2026.102661_bib68","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202501962","article-title":"ROS-Response nanoparticles for edaravone delivery: Pathological-Activated neuroprotection against ischemic-reperfusion injury in ischemic stroke","volume":"14","author":"Zhou","year":"2025","journal-title":"Adv Healthcare Mater"},{"key":"10.1016\/j.coph.2026.102661_sref69","first-page":"1","article-title":"Edaravone dexborneol for ischemic stroke with sufficient recanalization after thrombectomy: a randomized phase II trial","volume":"16","author":"Chen","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.coph.2026.102661_bib70","article-title":"Edaravone dexborneol for the treatment of acute ischemic stroke: a systematic review and meta-analysis","author":"Mortezaei","year":"2025","journal-title":"NeuroRadiol J"},{"key":"10.1016\/j.coph.2026.102661_bib71","doi-asserted-by":"crossref","DOI":"10.1007\/s00210-025-03950-1","article-title":"Efficacy and safety of edaravone dexborneol in acute ischemic stroke: systematic review and meta-analysis of randomized controlled trials","author":"Kashbour","year":"2025","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.coph.2026.102661_bib72","article-title":"Effect of edaravone dexborneol on clinical outcomes in patients with acute posterior circulation ischemic stroke undergoing endovascular therapy: a retrospective single-center study","volume":"105","author":"Luo","year":"2026","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.coph.2026.102661_bib73","first-page":"145","article-title":"Edaravone promotes motoneuron survival and functional recovery after brachial plexus root avulsion and reimplantation in rats: involvement of SIRT1\/TFEB pathway","author":"Jia","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.coph.2026.102661_bib74","doi-asserted-by":"crossref","DOI":"10.1177\/19714009251340319","article-title":"Edaravone dexborneol for the treatment of acute ischemic stroke: a systematic review and meta-analysis","volume":"39","author":"Mortezaei","year":"2026","journal-title":"NeuroRadiol J"},{"key":"10.1016\/j.coph.2026.102661_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.125087","article-title":"ROS-responsive quercetin-based polydopamine nanoparticles for targeting ischemic stroke by attenuating oxidative stress and neuroinflammation","volume":"669","author":"Jian","year":"2025","journal-title":"Int J Pharm"},{"key":"10.1016\/j.coph.2026.102661_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2024.148917","article-title":"Edaravone dexborneol attenuates cognitive impairment in a rat model of vascular dementia by inhibiting hippocampal oxidative stress and inflammatory responses and modulating the NMDA receptor signaling pathway","volume":"1833","author":"Guo","year":"2024","journal-title":"Brain Res"},{"key":"10.1016\/j.coph.2026.102661_bib77","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1508703","article-title":"Corrigendum: edaravone dexborneol treatment attenuates neuronal apoptosis and improves neurological function by suppressing 4-HNE-associated oxidative stress after subarachnoid hemorrhage","volume":"15","author":"Chen","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.coph.2026.102661_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111700","article-title":"Edaravone dexborneol alleviates ischemic injury and neuroinflammation by modulating microglial and astrocyte polarization while inhibiting leukocyte infiltration","volume":"130","author":"Wang","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.coph.2026.102661_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2025.123620","article-title":"Oxidative stress and inflammatory response in cerebral infarction due to hyperlipidemia and lipid-lowering, anti-inflammatory, and antioxidant therapy","author":"Zhou","year":"2025","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.coph.2026.102661_bib80","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1007\/s11030-024-10940-7","article-title":"Recent developments in the design of functional derivatives of edaravone and exploration of their antioxidant activities","volume":"29","author":"Mohan","year":"2025","journal-title":"Mol Divers"},{"key":"10.1016\/j.coph.2026.102661_bib81","article-title":"Pharmacological inhibition of ferroptosis as a therapeutic target for neurodegenerative diseases and strokes","volume":"10","author":"Wang","year":"2023","journal-title":"Adv Sci"},{"key":"10.1016\/j.coph.2026.102661_bib82","doi-asserted-by":"crossref","first-page":"988","DOI":"10.4103\/1673-5374.385284","article-title":"Ferroptosis: a potential therapeutic target for stroke","volume":"19","author":"Liu","year":"2024","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.coph.2026.102661_bib83","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0311231","article-title":"Synergistic effects of neuroprotective drugs with intravenous recombinant tissue plasminogen activator in acute ischemic stroke: a Bayesian network meta-analysis","volume":"19","author":"Dang","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.coph.2026.102661_bib84","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213949","article-title":"Clinical and safety outcomes of edaravone dexborneol in acute ischemic stroke: a multicenter, prospective, cohort Study","volume":"105","author":"Ma","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.coph.2026.102661_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108288","article-title":"Potential edaravone\/benzocyclopentenone derivatives alleviate cerebral ischemia reperfusion injury as neuroprotective agents","volume":"157","author":"Zeng","year":"2025","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.coph.2026.102661_sref86","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.71272","article-title":"Prospective open-label safety Study of edaravone dexborneol in Filipino patients with acute ischemic stroke","volume":"16","author":"Sabellano","year":"2026","journal-title":"Brain Behav"},{"key":"10.1016\/j.coph.2026.102661_bib87","doi-asserted-by":"crossref","DOI":"10.1080\/08941939.2026.2622138","article-title":"The effect of edaravone dexborneol treatment after intracranial vascular intervention on inflammatory factors and oxidative stress level in elderly patients with acute ischemic cerebrovascular disease","volume":"39","author":"Zhang","year":"2026","journal-title":"J Invest Surg"},{"key":"10.1016\/j.coph.2026.102661_bib88","doi-asserted-by":"crossref","DOI":"10.1161\/str.57.suppl_1.DP393","article-title":"Abstract DP393: integrated Neuro-Cardiac protection by edaravone-dexborneol in vascular dementia with Metabolic syndrome","volume":"57","author":"Niu","year":"2026","journal-title":"Stroke"},{"key":"10.1016\/j.coph.2026.102661_sref89","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(25)01862-8","article-title":"Efficacy and safety of minocycline in patients with acute ischaemic stroke (EMPHASIS): a multicentre, double-blind, randomised controlled trial","volume":"407","author":"Lu","year":"2026","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.coph.2026.102661_bib90","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1503\/jpn.100057","article-title":"N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action","volume":"36","author":"Dean","year":"2011","journal-title":"J Psychiatry Neurosci"},{"key":"10.1016\/j.coph.2026.102661_bib91","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0140-6736(12)60813-7","article-title":"Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial)","volume":"380","author":"D\u00e1valos","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2026.102661_bib92","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2217\/nmt-2020-0033","article-title":"Riluzole for the treatment of amyotrophic lateral sclerosis","volume":"10","author":"Saitoh","year":"2020","journal-title":"Neurodegener Dis Manag"},{"key":"10.1016\/j.coph.2026.102661_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2019.101328","article-title":"Insight into the mechanism of ferroptosis inhibition by ferrostatin-1","volume":"28","author":"Miotto","year":"2020","journal-title":"Redox Biol"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489226000573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489226000573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:03:29Z","timestamp":1788840209000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489226000573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":93,"alternative-id":["S1471489226000573"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2026.102661","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological basis of Edaravone\u2013Dexborneol neuroprotection: Integrated modulation of oxidative stress, neuroinflammation, and ferroptosis","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2026.102661","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102661"}}